The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
Open accessAbstract
BACKGROUND Individual patient data from two randomised trials comparing neoadjuvant chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to examine long-term outcomes for patients and to identify any preferable therapeutic approaches for subgroup populations. METHODS We did a per-protocol pooled analysis of individual patient data from the European Organisation for Research and Treatment of Cancer (EORTC) 55971 trial (NCT00003636) and the Medical Research Council Chemotherapy Or Upfront Surgery (CHORUS) trial (ISRCTN74802813). In the EORTC trial, eligible women had biopsy-proven International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or IV invasive epithelial tubo-ovarian carcinoma. In the CHORUS trial, inclusion criteria were similar to those of the EORTC trial, and women with apparent FIGO stage IIIA and IIIB disease were also eligible. The main aim of the pooled analysis was to show non-inferiority in overall survival with neoadjuvant chemotherapy compared with upfront debulking surgery, using the reverse Kaplan-Meier method. Tests for heterogeneity were based on Cochran's Q heterogeneity statistic. FINDINGS Data for 1220 women were included in the pooled analysis, 670 from the EORTC trial and 550 from the CHORUS trial. 612 women were randomly allocated to receive upfront debulking surgery and 608 to receive neoadjuvant chemotherapy. Median follow-up was 7·6 years (IQR 6·0-9·6; EORTC, 9·2 years [IQR 7·3-10·4]; CHORUS, 5·9 years [IQR 4·3-7·4]). Median age was 63 years (IQR 56-71) and median size of the largest metastatic tumour at diagnosis was 8 cm (IQR 4·8-13·0). 55 (5%) women had FIGO stage II-IIIB disease, 831 (68%) had stage IIIC disease, and 230 (19%) had stage IV disease, with staging data missing for 104 (9%) women. In the entire population, no difference in median overall survival was noted between patients who underwent neoadjuvant chemotherapy and upfront debulking surgery (27·6 months [IQR 14·1-51·3] and 26·9 months [12·7-50·1], respectively; hazard ratio [HR] 0·97, 95% CI 0·86-1·09; p=0·586). Median overall survival for EORTC and CHORUS patients was significantly different at 30·2 months (IQR 15·7-53·7) and 23·6 months (10·5-46·9), respectively (HR 1·20, 95% CI 1·06-1·36; p=0·004), but was not heterogeneous (Cochran's Q, p=0·17). Women with stage IV disease had significantly better outcomes with neoadjuvant chemotherapy compared with upfront debulking surgery (median overall survival 24·3 months [IQR 14·1-47·6] and 21·2 months [10·0-36·4], respectively; HR 0·76, 95% CI 0·58-1·00; p=0·048; median progression-free survival 10·6 months [7·9-15·0] and 9·7 months [5·2-13·2], respectively; HR 0·77, 95% CI 0·59-1·00; p=0·049). INTERPRETATION Long-term follow-up data substantiate previous results showing that neoadjuvant chemotherapy and upfront debulking surgery result in similar overall survival in advanced tubo-ovarian cancer, with better survival in women with stage IV disease with neoadjuvant chemotherapy. This pooled analysis, with long-term follow-up, shows that neoadjuvant chemotherapy is a valuable treatment option for patients with stage IIIC-IV tubo-ovarian cancer, particularly in patients with a high tumour burden at presentation or poor performance status. FUNDING National Cancer Institute and Vlaamse Liga tegen kanker (Flemish League against Cancer).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Self-citationPiaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Self-citationReporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Royston, P., & Parmar, M. K. B. (2011) · Statistics in Medicine · doi:10.1002/sim.4274 · Cited by 585
Self-citationWright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6907 · Cited by 409
Self-citationFagotti, A., Ferrandina, G., Vizzielli, G., Fanfani, F., Gallotta, V., Chiantera, V., Costantini, B., Margariti, P. A., Gueli Alletti, S., Cosentino, F., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.017 · Cited by 395
Cited by
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Self-citationFagotti, A., Ferrandina, M. G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., Margariti, P. A., Chiantera, V., Costantini, B., Gueli Alletti, S., et al. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001640 · Cited by 451
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Berek, J. S., Chen, L.-M., Cristea, M., DeRosa, M., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0039 · Cited by 309
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Metadata
- Authors
- Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., Jayson, G. C., Johnson, N., Swart, A. M., Verheijen, R., McCluggage, W. G., Perren, T., Panici, P. B., Kenter, G., Casado, A., Mendiola, C., Stuart, G., Reed, N. S., Kehoe, S., Tropé G., C., Dobbs, S., Essapen, S., Hoskins, P., Green, J., Gilby, E., Van Baal, M., Twigg, J., Van Der Burg, M. E. L., Godfrey, K., Lacave, A. J., Angioli, R., Nath, R., Chin, K., Redman, C., Lotocki, R., Olaitan, A., Mosgaard, B., Rustin, G., Ind, T., Persic, M., Hogg, M., Van Der Velden, J., Ledermann, J., Peter Sykes, P. S., Madhavan, K., Kannisto, P., Hird, V., Evans, A., Sandvei R., R., Gauthier, P., Cruickshank, D. J., Ottevanger, P. B., Pearson, S., Kitchener, H., Hall, M., Bessette, P., Pecorelli, S., Gerdin, E., Lopes, T., Fish, A., Barlow., C., Van Eygen, K., Floquet, A., Tholander, B., Gul, N., Gornall, R., Luesley, D., Kirwan, P., Symonds, P., Henry, R., Poole, D., McNeish, I., Hocking, M., Sammaraie, A., Speiser, P., Leblanc, E., Green, J. A., De Oliveira, C. F., Grimshaw, R., Zola, P., Parkin, D., Luesley, D., Lamb, M., Hong, A., Gillespie, A., Hamid, A., Ahmed, A., Plante, M., De Valk, B., Nordin, A., Clamp, A., Perez, D., Graham Dark, G. D., Ferguson, M., MacGregor, C., Skailes, G., Jones, R., Gillespie, A., Cawdell, G., Leeson, S., Elit, L., Dittrich, C., Gotlieb, W., Poole, D., Cullimore, J., Crosse, B., Ridley, P., Head, A., Nieto, J., Awwad, S., Brinkmann, D., Eustace, D., Hindley, A., Katsaros, D., Popadiuk, C., Kristeller, T., Redman, C., Chan, S., Marth, C., Yiannakis, D., Lankaster, K., Beynon, G., Suhail, A., Indrajit, F., Hong, A., Quigley, M., Adeyemi, O., Persic, M., Lofts, F., McNally, O., Tristam, A., Lee, M., Counsell, R., Gleeson, N., Papadopoulos, A., Maggino, T., Honkoop, A., Ghatage, P., Vermorken, J. B., De Greve, J., Boman, K., Petru, E., & Amant, F.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 19
- Issue
- 12
- Pages
- 1680-1687
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2900298813
- Cited by
- 306
- References
- 18
- FWCI
- 24.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30566-7
- The paper
- Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., Jayson, G. C., Johnson, N., Swart, A. M., Verheijen, R., McCluggage, W. G., Perren, T., Panici, P. B., Kenter, G., Casado, A., Mendiola, C., Stuart, G., Reed, N. S., Kehoe, S., . . . Amant, F. (2018). Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30566-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.